Resha Boodhram

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis”.

Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis

Clinical Infectious Diseases(2022)10.1093/cid/ciac232

N/A

0.743DataRank · unranked

22 citations

Allison Wolf, Benjamin Chimukangara, James C. M. Brust, Richard Lessells, K. Rivet Amico +8 more

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

BMJ Open(2022)10.1136/bmjopen-2022-067765

N/A

0.484DataRank · unranked

7 citations

Kelly E. Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende‐Zuma, Rubeshan Perumal +4 more

Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial

The Lancet HIV(2025)10.1016/s2352-3018(25)00200-0

N/A

0.165DataRank · unranked

2 citations

Kogieleum Naidoo, Marothi Letsoalo, Roeland E. Wasmann, Gillian Dorse, Rubeshan Perumal +33 more

Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus

Clinical Infectious Diseases(2020)10.1093/cid/ciaa1557

N/A

0DataRank · unranked

31 citations

Amrita Daftary, Christina Hwang, Amy S. Labar, Resha Boodhram, Bhavna Maharaj +9 more

Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study

The Lancet Global Health(2021)10.1016/s2214-109x(20)30548-9

N/A

0DataRank · unranked

52 citations

Shinjini Mondal, Jennifer Zelnick, Gerald Friedland, Boitumelo Seepamore, Resha Boodhram +4 more

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin

Clinical Infectious Diseases(2025)10.1093/cid/ciaf732

N/A

0DataRank · unranked

0 citations

Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, Kogieleum Naidoo, R Perumal, James F Rooney +32 more